49 results on '"Redpath CJ"'
Search Results
2. Role of Nuclear Imaging in Cardiac Stereotactic Body Radiotherapy for Ablation of Ventricular Tachycardia.
- Author
-
Haberl C, Crean AM, Zelt JGE, Redpath CJ, and deKemp RA
- Subjects
- Humans, Radionuclide Imaging, Tachycardia, Ventricular diagnostic imaging, Tachycardia, Ventricular radiotherapy, Tachycardia, Ventricular surgery, Radiosurgery methods
- Abstract
Ventricular tachycardia (VT) is a life-threatening arrhythmia common in patients with structural heart disease or nonischemic cardiomyopathy. Many VTs originate from regions of fibrotic scar tissue, where delayed electrical signals exit scar and re-enter viable myocardium. Cardiac stereotactic body radiotherapy (SBRT) has emerged as a completely noninvasive alternative to catheter ablation for the treatment of recurrent or refractory ventricular tachycardia. While there is no common consensus on the ideal imaging workflow, therapy planning for cardiac SBRT often combines information from a plurality of imaging modalities including MRI, CT, electroanatomic mapping and nuclear imaging. MRI and CT provide detailed anatomic information, and late enhancement contrast imaging can indicate regions of fibrosis. Electroanatomic maps indicate regions of heterogenous conduction voltage or early activation which are indicative of arrhythmogenic tissue. Some early clinical adopters performing cardiac SBRT report the use of myocardial perfusion and viability nuclear imaging to identify regions of scar. Nuclear imaging of hibernating myocardium, inflammation and sympathetic innervation have been studied for ventricular arrhythmia prognosis and in research relating to catheter ablation of VT but have yet to be studied in their potential applications for cardiac SBRT. The integration of information from these many imaging modalities to identify a target for ablation can be challenging. Multimodality image registration and dedicated therapy planning tools may enable higher target accuracy, accelerate therapy planning workflows and improve patient outcomes. Understanding the pathophysiology of ventricular arrhythmias, and localizing the arrhythmogenic tissues, is vital for successful ablation with cardiac SBRT. Nuclear imaging provides an arsenal of imaging strategies to identify regional scar, hibernation, inflammation, and sympathetic denervation with some advantages over alternative imaging strategies., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Connor Haberl reports financial support was provided by Natural Sciences and Engineering Research Council of Canada. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
3. Long-Term Outcomes of Resynchronization-Defibrillation for Heart Failure.
- Author
-
Sapp JL, Sivakumaran S, Redpath CJ, Khan H, Parkash R, Exner DV, Healey JS, Thibault B, Sterns LD, Lam NHN, Manlucu J, Mokhtar A, Sumner G, McKinlay S, Kimber S, Mondesert B, Talajic M, Rouleau J, McCarron CE, Wells G, and Tang ASL
- Subjects
- Humans, Kaplan-Meier Estimate, Stroke Volume, Treatment Outcome, Ventricular Function, Left, Electrocardiography, Follow-Up Studies, Time Factors, Cardiac Resynchronization Therapy, Defibrillators, Implantable, Heart Failure mortality, Heart Failure physiopathology, Heart Failure therapy
- Abstract
Background: The Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) showed a greater benefit with respect to mortality at 5 years among patients who received cardiac-resynchronization therapy (CRT) than among those who received implantable cardioverter-defibrillators (ICDs). However, the effect of CRT on long-term survival is not known., Methods: We randomly assigned patients with New York Heart Association (NYHA) class II or III heart failure, a left ventricular ejection fraction of 30% or less, and an intrinsic QRS duration of 120 msec or more (or a paced QRS duration of 200 msec or more) to receive either an ICD alone or a CRT defibrillator (CRT-D). We assessed long-term outcomes among patients at the eight highest-enrolling participating sites. The primary outcome was death from any cause; the secondary outcome was a composite of death from any cause, heart transplantation, or implantation of a ventricular assist device., Results: The trial enrolled 1798 patients, of whom 1050 were included in the long-term survival trial; the median duration of follow-up for the 1050 patients was 7.7 years (interquartile range, 3.9 to 12.8), and the median duration of follow-up for those who survived was 13.9 years (interquartile range, 12.8 to 15.7). Death occurred in 405 of 530 patients (76.4%) assigned to the ICD group and in 370 of 520 patients (71.2%) assigned to the CRT-D group. The time until death appeared to be longer for those assigned to receive a CRT-D than for those assigned to receive an ICD (acceleration factor, 0.80; 95% confidence interval, 0.69 to 0.92; P = 0.002). A secondary-outcome event occurred in 412 patients (77.7%) in the ICD group and in 392 (75.4%) in the CRT-D group., Conclusions: Among patients with a reduced ejection fraction, a widened QRS complex, and NYHA class II or III heart failure, the survival benefit associated with receipt of a CRT-D as compared with ICD appeared to be sustained during a median of nearly 14 years of follow-up. (RAFT ClinicalTrials.gov number, NCT00251251.)., (Copyright © 2024 Massachusetts Medical Society.)
- Published
- 2024
- Full Text
- View/download PDF
4. High-power short-duration versus low-power long-duration ablation for pulmonary vein isolation: A substudy of the AWARE randomized controlled trial.
- Author
-
Joza J, Nair GM, Birnie DH, Nery PB, Redpath CJ, Sarrazin JF, Champagne J, Bernick J, Wells GA, and Essebag V
- Subjects
- Humans, Treatment Outcome, Recurrence, Pulmonary Veins surgery, Atrial Fibrillation diagnosis, Atrial Fibrillation surgery, Catheter Ablation adverse effects
- Abstract
Introduction: Pulmonary vein isolations (PVI) are being performed using a high-power, short-duration (HPSD) strategy. The purpose of this study was to compare the clinical efficacy and safety outcomes of an HPSD versus low-power, long-duration (LPLD) approach to PVI in patients with paroxysmal atrial fibrillation (AF)., Methods: Patients were grouped according to a HPSD (≥40 W) or LPLD (≤35 W) strategy. The primary endpoint was the 1-year recurrence of any atrial arrhythmia lasting ≥30 s, detected using three 14-day ambulatory continuous ECG monitoring. Procedural and safety endpoints were also evaluated. The primary analysis were regression models incorporating propensity scores yielding adjusted relative risk (RR
a ) and mean difference (MDa ) estimates., Results: Of the 398 patients included in the AWARE Trial, 173 (43%) underwent HPSD and 225 (57%) LPLD ablation. The distribution of power was 50 W in 75%, 45 W in 20%, and 40 W in 5% in the HPSD group, and 35 W with 25 W on the posterior wall in the LPLD group. The primary outcome was not statistically significant at 30.1% versus 22.2% in HPSD and LPLD groups with RRa 0.77 (95% confidence interval [CI]) 0.55-1.10; p = .165). The secondary outcome of repeat catheter ablation was not statistically significant at 6.9% and 9.8% (RRa 1.59 [95% CI 0.77-3.30]; p = .208) respectively, nor was the incidence of any ECG documented AF during the blanking period: 1.7% versus 8.0% (RRa 3.95 [95% CI 1.00-15.61; p = .049) in the HPSD versus LPLD group respectively. The total procedure time was significantly shorter in the HPSD group (MDa 97.5 min [95% CI 84.8-110.4)]; p < .0001) with no difference in adjudicated serious adverse events., Conclusions: An HPSD strategy was associated with significantly shorter procedural times with similar efficacy in terms of clinical arrhythmia recurrence. Importantly, there was no signal for increased harm with a HPSD strategy., (© 2023 Wiley Periodicals LLC.)- Published
- 2024
- Full Text
- View/download PDF
5. How much endocardial scar homogenization is required for successful ablation of ischemic ventricular tachycardia?
- Author
-
Thibert MJ, Odabashian R, Lepage-Ratte MF, Jones A, Alqarawi W, Nery PB, Nair GM, Davis DR, Golian M, Redpath CJ, Hansom S, Ramirez FD, Aydin A, Klein A, Green MS, Birnie DH, and Sadek MM
- Subjects
- Humans, Cicatrix, Arrhythmias, Cardiac surgery, Treatment Outcome, Tachycardia, Ventricular surgery, Myocardial Ischemia complications, Myocardial Ischemia surgery, Catheter Ablation
- Published
- 2023
- Full Text
- View/download PDF
6. Standard vs Augmented Ablation of Paroxysmal Atrial Fibrillation for Reduction of Atrial Fibrillation Recurrence: The AWARE Randomized Clinical Trial.
- Author
-
Nair GM, Birnie DH, Nery PB, Redpath CJ, Sarrazin JF, Roux JF, Parkash R, Bernier M, Sterns LD, Sapp J, Novak P, Veenhuyzen G, Morillo CA, Singh SM, Sadek MM, Golian M, Klein A, Sturmer M, Chauhan VS, Angaran P, Green MS, Bernick J, Wells GA, and Essebag V
- Subjects
- Humans, Female, Middle Aged, Male, Prospective Studies, Electrocardiography, Ambulatory, Atrial Fibrillation drug therapy, Atrial Flutter, Pulmonary Veins surgery, Catheter Ablation adverse effects
- Abstract
Importance: Recurrent atrial fibrillation (AF) commonly occurs after catheter ablation and is associated with patient morbidity and health care costs., Objective: To evaluate the superiority of an augmented double wide-area circumferential ablation (WACA) compared with a standard single WACA in preventing recurrent atrial arrhythmias (AA) (atrial tachycardia, atrial flutter, or atrial fibrillation [AF]) in patients with paroxysmal AF., Design, Setting, and Participants: This was a pragmatic, multicenter, prospective, randomized, open, blinded end point superiority clinical trial conducted at 10 university-affiliated centers in Canada. The trial enrolled patients 18 years and older with symptomatic paroxysmal AF from March 2015 to May 2017. Analysis took place between January and April 2022. Analyses were intention to treat., Interventions: Patients were randomized (1:1) to receive radiofrequency catheter ablation for pulmonary vein isolation with either a standard single WACA or an augmented double WACA., Main Outcomes and Measures: The primary outcome was AA recurrence between 91 and 365 days postablation. Patients underwent 42 days of ambulatory electrocardiography monitoring after ablation. Secondary outcomes included need for repeated catheter ablation and procedural and safety variables., Results: Of 398 patients, 195 were randomized to the single WACA (control) arm (mean [SD] age, 60.6 [9.3] years; 65 [33.3%] female) and 203 to the double WACA (experimental) arm (mean [SD] age, 61.5 [9.3] years; 66 [32.5%] female). Overall, 52 patients (26.7%) in the single WACA arm and 50 patients (24.6%) in the double WACA arm had recurrent AA at 1 year (relative risk, 0.92; 95% CI, 0.66-1.29; P = .64). Twenty patients (10.3%) in the single WACA arm and 15 patients (7.4%) in the double WACA arm underwent repeated catheter ablation (relative risk, 0.72; 95% CI, 0.38-1.36). Adjudicated serious adverse events occurred in 13 patients (6.7%) in the single WACA arm and 14 patients (6.9%) in the double WACA arm., Conclusions and Relevance: In this randomized clinical trial of patients with paroxysmal AF, additional ablation by performing a double ablation lesion set did not result in improved freedom from recurrent AA compared with a standard single ablation set., Trial Registration: ClinicalTrials.gov Identifier: NCT02150902.
- Published
- 2023
- Full Text
- View/download PDF
7. Metabolic activity of the left and right atria are differentially altered in patients with atrial fibrillation and LV dysfunction.
- Author
-
Santi ND, Wu KY, Redpath CJ, Nery PB, Huang W, Burwash IG, Bernick J, Wells GA, McArdle B, Chow BWJ, Birnie DH, Garrard L, deKemp RA, and Beanlands RSB
- Subjects
- Humans, Fluorodeoxyglucose F18 metabolism, Heart Atria diagnostic imaging, Heart Atria metabolism, Myocardium metabolism, Atrial Fibrillation metabolism, Ventricular Dysfunction, Left
- Abstract
Background: Alterations in atrial metabolism may play a role in the perpetuation of atrial fibrillation (AF). This study sought to compare
18 F-fluorodeoxyglucose (FDG) uptake on PET, in patients with LV dysfunction versus those without AF., Methods: Seventy-two patients who underwent myocardial viability assessment were evaluated. AF patients (36) had persistent or permanent AF based on history and ECG. Patients without AF (36) were matched to AF patients based on sex, diabetes, age, and LVEF. Maximum and mean FDG Standard Uptake Values (SUV) in the left atrial (LA) wall and right atrial (RA) wall were measured. Tissue-to-blood ratios (TBR) were calculated as atrial wall to blood-pool activity. Atrial volumes were measured by echocardiography., Results: Maximum and mean FDG SUV and TBRs were significantly increased in the RA (but not the LA) of patients with AF compared to those without (P < 0.01). When accounting for changes in atrial volume, the presence of AF remained a significant predictor of higher RAMAX , but not RAMEAN FDG uptake., Conclusion: In patients with LV dysfunction from ischemic cardiomyopathy, LA and RA glucose metabolism are differentially altered in those with persistent atrial fibrillation. Further investigations should elucidate the temporal relationship between AF and glucose metabolic changes, as a potential target for therapy., (© 2022. The Author(s) under exclusive licence to American Society of Nuclear Cardiology.)- Published
- 2022
- Full Text
- View/download PDF
8. Characterization of arrhythmia substrate to ablate persistent atrial fibrillation (COAST-AF): Randomized controlled trial design and rationale.
- Author
-
Nery PB, Wells GA, Verma A, Joza J, Nair GM, Veenhuyzen G, Andrade J, Nault I, Wong JA, Sikkel M, Essebag V, Macle L, Sapp J, Roux JF, Skanes A, Angaran P, Novak P, Redfearn D, Golian M, Redpath CJ, Sturmer M, and Birnie D
- Subjects
- Humans, Prospective Studies, Quality of Life, Treatment Outcome, Recurrence, Atrial Fibrillation surgery, Pulmonary Veins surgery, Catheter Ablation methods
- Abstract
Background: Atrial low voltage area (LVA) catheter ablation has emerged as a promising strategy for ablation of persistent atrial fibrillation (AF). It is unclear if catheter ablation of atrial LVA increases treatment success rates in patients with persistent AF., Objective: The primary aim of this trial is to assess the potential benefit of adjunctive catheter ablation of atrial LVA in addition to pulmonary vein isolation (PVI) in patients with persistent AF, when compared to PVI alone. The secondary aims are to evaluate safety outcomes, the quality of life and the healthcare resource utilization., Methods/design: A multicenter, prospective, parallel-group, 2-arm, single-blinded randomized controlled trial is under way (NCT03347227). Patients who are candidates for catheter ablation for persistent AF will be randomly assigned (1:1) to either PVI alone or PVI + atrial LVA ablation. The primary outcome is 18-month documented event rate of atrial arrhythmia (AF, atrial tachycardia or atrial flutter) post catheter ablation. Secondary outcomes include procedure-related complications, freedom from atrial arrhythmia at 12 months, AF burden, need for emergency department visits/hospitalization, need for repeat ablation for atrial arrhythmia, quality of life at 12 and 18 months, ablation time, and procedure duration., Discussion: Characterization of Arrhythmia Mechanism to Ablate Atrial Fibrillation (COAST-AF) is a multicenter randomized trial evaluating ablation strategies for catheter ablation. We hypothesize that catheter ablation of atrial LVA in addition to PVI will result in higher procedural success rates when compared to PVI alone in patients with persistent AF., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
9. Correction to: Outcomes of a comprehensive strategy during repeat atrial fibrillation ablation.
- Author
-
Weng W, Birnie DH, Ramirez FD, Van Stiphout C, Golian M, Nery PB, Hansom SP, Redpath CJ, Klein A, Nair GM, Alqarawi W, Green MS, Davis DR, Santangeli P, Schaller RD, Marchlinski FE, and Sadek MM
- Published
- 2022
- Full Text
- View/download PDF
10. Outcomes of a comprehensive strategy during repeat atrial fibrillation ablation.
- Author
-
Weng W, Birnie DH, Ramirez FD, Van Stiphout C, Golian M, Nery PB, Hansom SP, Redpath CJ, Klein A, Nair GM, Alqarawi W, Green MS, Davis DR, Santangeli P, Schaller RD, Marchlinski FE, and Sadek MM
- Subjects
- Humans, Prospective Studies, Recurrence, Treatment Outcome, Atrial Fibrillation, Catheter Ablation methods, Pulmonary Veins surgery, Atrial Flutter surgery
- Abstract
Background/purpose: Atrial fibrillation (AF) recurs post-ablation in 30-40% of patients. The approach to a repeat ablation, beyond isolation of reconnected pulmonary veins (PVs), is not well established. We sought to prospectively assess outcomes and predictors of recurrence among consecutive patients who underwent repeat AF ablation with a standardized approach., Methods: This was a single-center prospective study of consecutive patients who underwent repeat AF ablation. Our protocol consisted of six steps: PV re-isolation, ablation of left atrial low-voltage areas (LVAs), ablation of isoproterenol-induced non-PV triggers, electrophysiology study (EPS) and ablation of induced AVNRT/AVRT, ablation of induced clinical atrial flutters, and lastly empiric ablation as per operator discretion if no other ablation was performed., Results: Among 725 AF ablations performed during the study period, 74 were repeat ablations. Of those undergoing repeat ablation, 53 (72%) had PV reconnection, 30 (41%) had LVAs, seven (10%) had non-PV triggers, five (7%) had AVNRT, and 15 (20%) had typical atrial flutter. Following repeat ablation, arrhythmia-free survival was 65% at 1 year. The absence of PV reconnection was the only factor independently associated with recurrence after repeat ablation (recurrence rate 71%, adjusted OR 7.91, 95% CI 2.31-27.16, p = 0.001)., Conclusions: A comprehensive approach to repeat AF ablation including PV re-isolation, LVA ablation, non-PV trigger ablation, EPS, and flutter ablation was associated with a 65% 1-year arrhythmia-free survival. The absence of PV reconnection was the only independent predictor of arrhythmia recurrence. Further research is needed to identify therapies beyond PV isolation for patients undergoing repeat ablation., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
11. Augmented wide area circumferential catheter ablation for reduction of atrial fibrillation recurrence (AWARE) trial: Design and rationale.
- Author
-
Nair GM, Birnie DH, Wells GA, Nery PB, Redpath CJ, Sarrazin JF, Roux JF, Parkash R, Bernier M, Sterns LD, Novak P, Veenhuyzen G, Morillo CA, Singh SM, Sturmer M, Chauhan VS, Angaran P, and Essebag V
- Subjects
- Canada, Humans, Prospective Studies, Quality of Life, Recurrence, Treatment Outcome, Atrial Fibrillation, Catheter Ablation methods, Pulmonary Veins surgery
- Abstract
Background: Recurrence of atrial fibrillation (AF) after a pulmonary vein isolation procedure is often due to electrical reconnection of the pulmonary veins. Repeat ablation procedures may improve freedom from AF but are associated with increased risks and health care costs. A novel ablation strategy in which patients receive "augmented" ablation lesions has the potential to reduce the risk of AF recurrence., Objective: The Augmented Wide Area Circumferential Catheter Ablation for Reduction of Atrial Fibrillation Recurrence (AWARE) Trial was designed to evaluate whether an augmented wide-area circumferential antral (WACA) ablation strategy will result in fewer atrial arrhythmia recurrences in patients with symptomatic paroxysmal AF, compared with a conventional WACA strategy., Methods/design: The AWARE trial was a multicenter, prospective, randomized, open, blinded endpoint trial that has completed recruitment (ClinicalTrials.gov NCT02150902). Patients were randomly assigned (1:1) to either the control arm (single WACAlesion set) or the interventional arm (augmented- double WACA lesion set performed after the initial WACA). The primary outcome was atrial tachyarrhythmia (AA; atrial tachycardia [AT], atrial flutter [AFl] or AF) recurrence between days 91 and 365 post catheter ablation. Patient follow-up included 14-day continuous ambulatory ECG monitoring at 3, 6, and 12 months after catheter ablation. Three questionnaires were administered during the trial- the EuroQuol-5D (EQ-5D) quality of life scale, the Canadian Cardiovascular Society Severity of Atrial Fibrillation scale, and a patient satisfaction scale., Discussion: The AWARE trial was designed to evaluate whether a novel approach to catheter ablation reduced the risk of AA recurrence in patients with symptomatic paroxysmal AF., Competing Interests: Conflicts of interest Dr Girish M. Nair reports honoraria, speaking fees and grant support from Biosense Webster Inc and Boston Scientific Inc related to Atrial Fibrillation (Modest). Dr Pablo B. Nery reports honoraria, speaking fees and grant support from Biosense Webster Canada, not related to this work (Modest). Dr David H. Birnie reports grants from Boehringer Ingelheim, Germany, grants from Pfizer and Bristol-Myers Squibb, New York (Modest). Dr George Veenhuyzen has received honoraria & consulting fees from Medtronic, BMS-Pfizer, Servier, & Biotronik. Dr Jean-Francois Sarrazin has received consulting fees from Biosense Webster. Dr Jean-Francois Roux has received consulting feeds from Biosense Webster. Dr Carlos A. Morillo has received honoraria/consulting fees from Abbott, Biosense Webster, Boston Scientific, and Medtronic for AF related lectures and research support. Dr Ratika Parkash has received consulting fees/honoraria and research support from Abbott, Biosense Webster and Medtronic Inc Dr Vijay S. Chauhan has received consulting fees/honoraria and research support from Biosense Webster Inc Dr Vidal Essebag has received honoraria from Abbott, Biosense Webster, Boston Scientific, and Medtronic. The other authors have no disclosures related to this publication., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
12. Rhythm-Monitoring Strategy and Arrhythmia Recurrence in Atrial Fibrillation Ablation Trials: A Systematic Review.
- Author
-
Unni RR, Prager RT, Odabashian R, Zhang JJ, Fat Hing NN, Nery PB, Pi L, Aldawood W, Sadek MM, Redpath CJ, Birnie DH, Alqarawi W, Zagzoog A, Golian M, Klein A, Ramirez FD, Green MS, Chen L, Visintini S, Wells GA, and Nair GM
- Abstract
Background: : The rhythm-monitoring strategy after catheter ablation (CA) for atrial fibrillation (AF) impacts the detection of atrial arrhythmia recurrence and is not well characterized. We performed a systematic review and meta-regression analysis to determine whether the duration and mode of rhythm monitoring after CA affects detection of atrial arrhythmia recurrence., Methods: Databases were systematically searched for randomized controlled trials of adult patients undergoing first CA for AF from 2007 to 2021. Duration and strategy of rhythm monitoring were extracted. Meta-regression was used to identify any association between duration of monitoring and detection of atrial arrhythmia recurrence. The primary measure of outcome was single-procedure recurrence of atrial arrhythmia., Results: The search strategy yielded 57 trial arms from 56 randomized controlled trials comprising 5322 patients: 36 arms of patients with paroxysmal AF (PAF), and 21 arms of patients with persistent AF (PeAF) or both PAF/PeAF. Intermittent monitoring was associated with detection of significantly less atrial arrhythmia recurrence than continuous monitoring in PAF arms (31.2% vs 46.9%, P = 0.001), but not in PeAF/PAF-PeAF combined arms (43.3% vs 63.6%, P = 0.12). No significant relationship was seen between the duration of intermittent rhythm monitoring and atrial arrhythmia recurrence detection in either the PAF ( P = 0.93) or PeAF/PAF-PeAF combined arms ( P = 0.20)., Conclusions: Continuous rhythm monitoring detected higher atrial arrhythmia recurrence rates, compared to intermittent rhythm monitoring, in patients with PAF. The duration of intermittent monitoring did not show a statistically significant relationship to the yield of arrhythmia detection, in near identical cohorts of trial subjects undergoing similar interventions, with clinical and research implications., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
13. Cardiac Implantable Devices Management in Medical Assistance in Dying (MAiD): Review and Recommendations for Cardiac Device Clinics.
- Author
-
Chakrabarti S, Gibson JA, Bennett MT, Toma M, Verma AT, Chow R, Plewes L, Redpath CJ, Mondésert B, Sterns L, and Krahn AD
- Subjects
- Canada, Humans, Terminal Care methods, Cardiovascular Diseases therapy, Defibrillators, Implantable, Guidelines as Topic, Medical Assistance organization & administration, Terminal Care standards, Terminally Ill
- Abstract
The Medical Assistance in Dying (MAiD) program has been steadily expanding in Canada, and is expected to continue to do so. There are a substantial number of Canadians with pacemakers and defibrillators, many of whom are potential MAiD recipients. There is a need for review and reflection of standardisation of cardiac device management in MAiD patients, not only because of ethical concerns, but also because of the complexity of management at end of life. This document examines the status and role of cardiac devices (pacemakers and intracardiac defibrillators) and their physiologic interactions and influences during the MAiD process, and provides recommendations for their management., (Copyright © 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
14. High-power, short-duration atrial fibrillation ablation compared with a conventional approach: Outcomes and reconnection patterns.
- Author
-
Hansom SP, Alqarawi W, Birnie DH, Golian M, Nery PB, Redpath CJ, Klein A, Green MS, Davis DR, Sheppard-Perkins E, Ramirez FD, Nair GM, and Sadek MM
- Subjects
- Humans, Recurrence, Time Factors, Treatment Outcome, Atrial Fibrillation diagnosis, Atrial Fibrillation surgery, Catheter Ablation adverse effects, Pulmonary Veins diagnostic imaging, Pulmonary Veins surgery
- Abstract
Background: The effectiveness, safety, and pulmonary vein (PV) reconnection patterns of point-by-point high-power, short-duration (HPSD) ablation relative to conventional force-time integral (FTI)-guided strategies for atrial fibrillation (AF) ablation are unknown., Objectives: To compare 1-year freedom from atrial arrhythmia (AA), complication rates, procedural times, and PV reconnection patterns with HPSD AF AF ablation versus an FTI-guided low-power, long-duration (LPLD) strategy., Methods: We compared consecutive patients undergoing a first ablation procedure for paroxysmal or persistent AF. The HPSD protocol utilized a power of 50 W and durations of 6-8 s posteriorly and 8-10 s anteriorly. The LPLD protocol was FTI-guided with a power of ≤25 W posteriorly (FTI ≥ 300g·s) and ≤35 W anteriorly (FTI ≥ 400g·s)., Results: In total, 214 patients were prospectively included (107 HPSD, 107 LPLD). Freedom from AA at 1 year was achieved in 79% in the HPSD group versus 73% in the LPLD group (p = .339; adjusted hazard ratio with HPSD, 0.67; 95% confidence interval, 0.36-1.23; p < .004 for non-inferiority). Procedure duration was shorter in the HPSD group (229 ± 60 vs. 309 ± 77 min; p < .005). Patients undergoing repeat ablation had a higher propensity for reconnection at the right PV carina in the HPSD group compared with the LPLD group (14/30 = 46.7% vs. 7/34 = 20.6%; p = .035). There were no differences in complication rates., Conclusion: HPSD AF ablation resulted in similar freedom from AAs at 1 year, shorter procedure times, and a similar safety profile when compared with an LPLD ablation strategy. Patients undergoing HPSD ablation required more applications at the right carina to achieve isolation, and had a significantly higher rate of right carinal reconnections at redo procedures., (© 2021 Wiley Periodicals LLC.)
- Published
- 2021
- Full Text
- View/download PDF
15. Prevalence of Left Atrial Appendage Thrombus in Patients Anticoagulated With Direct Oral Anticoagulants: Systematic Review and Meta-analysis.
- Author
-
Alqarawi W, Grose E, Ramirez FD, Sikora L, Golian M, Nair GM, Nery PB, Klein A, Davis D, Green MS, Redpath CJ, Birnie DH, Burwash I, and Sadek MM
- Abstract
Background: Multiple studies have examined the prevalence of left atrial appendage thrombus (LAAT) in patients anticoagulated with direct oral anticoagulants (DOACs) and have reported conflicting results., Methods: Studies reporting the prevalence of LAAT on transesophageal echocardiography (TEE) after 3 or more weeks of DOAC therapy were identified. The proportions of anticoagulated patients diagnosed with LAAT were pooled using random-effects models. Prespecified subgroup analyses by the indication of TEE (pre-atrial fibrillation [AF] ablation vs cardioversion) and TEE strategy (routine use vs selective) were conducted via stratification., Results: Forty studies were identified: 22 full manuscripts and 18 abstracts. Only 11 studies performed TEE routinely. Most studies included patients with paroxysmal AF and low thromboembolic risk. The pooled prevalence of LAAT was 2.5% (95% confidence interval [1.6%-3.4%]). The prevalence of LAAT is lower in the pre-AF ablation group compared with pre-cardioversion (1.1% vs 4.0%, P = 0.033). Routine TEE strategy yielded a lower LAAT prevalence in both groups (0.1% vs 2.3%, P = 0.002 and 3.2% vs 5.8%, P = 0.432, respectively)., Conclusion: The reported prevalence of LAAT on TEE in patients treated with DOACs is highly variable. Factors associated with a high LAAT prevalence were pre-cardioversion indication and selective TEE strategy. Routine use of TEE before AF ablation may not be warranted., (© 2020 Canadian Cardiovascular Society. Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
16. Catheter Ablation of Low-Voltage Areas for Persistent Atrial Fibrillation: Procedural Outcomes Using High-Density Voltage Mapping.
- Author
-
Nery PB, Alqarawi W, Nair GM, Sadek MM, Redpath CJ, Golian M, Al Dawood W, Chen L, Hansom SP, Klein A, Wells GA, and Birnie DH
- Subjects
- Canada, Diagnosis, Computer-Assisted, Female, Heart Conduction System physiopathology, Heart Conduction System surgery, Humans, Male, Middle Aged, Outcome and Process Assessment, Health Care, Recurrence, Secondary Prevention methods, Secondary Prevention statistics & numerical data, Treatment Outcome, Atrial Fibrillation diagnosis, Atrial Fibrillation physiopathology, Atrial Fibrillation surgery, Catheter Ablation adverse effects, Catheter Ablation instrumentation, Electrophysiologic Techniques, Cardiac methods, Pulmonary Veins surgery
- Abstract
Background: Several approaches have been proposed to address the challenge of catheter ablation of persistent atrial fibrillation (AF). However, the optimal ablation strategy is unknown. We sought to evaluate the efficacy of pulmonary vein isolation (PVI) plus low-voltage area (LVA) ablation using contemporary high-density mapping to identify LVA in patients with persistent AF., Methods: Consecutive patients accepted for AF catheter ablation were studied. High-density bipolar voltage mapping data were acquired in sinus rhythm using multipolar catheters to detect LVA (defined as bipolar voltage < 0.5 mV). Semiautomated impedance-based software was used to ensure catheter contact during data collection. Patients underwent PVI + LVA ablation (if LVA present)., Results: A total of 145 patients were studied; 95 patients undergoing PVI + LVA ablation were compared with 50 controls treated with PVI only. Average age was 61 ± 10 years, and 80% were male. Baseline characteristics were comparable. Freedom from atrial tachycardia/AF at 18 months was 72% after PVI + LVA ablation vs 58% in controls (P = 0.022). Median procedure duration (273 [240, 342] vs 305 [262, 360] minutes; P = 0.019) and radiofrequency delivery (50 [43, 63] vs 55 [35, 68] minutes; P = 0.39) were longer in the PVI + LVA ablation group. Multivariable analysis showed that the ablation strategy (PVI + LVA) was the only independent predictor of freedom from atrial tachycardia/AF (hazard ratio, 0.53; 95% confidence interval, 0.29-0.96; P = 0.036). There were no adverse safety outcomes associated with LVA ablation., Conclusions: An individualized strategy of high-density mapping to assess the atrial substrate followed by PVI combined with LVA ablation is associated with improved outcomes. Adequately powered randomized clinical trials are needed to determine the role of PVI + LVA ablation for persistent AF., (Copyright © 2020 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
17. A new electrocardiographic definition of left bundle branch block (LBBB) in patients after transcatheter aortic valve replacement (TAVR).
- Author
-
Alqarawi W, Sadek MM, Golian M, Hibbert B, Redpath CJ, Nair GM, Nery PB, Davis DR, Klein A, Birnie DH, and Green MS
- Subjects
- Aged, 80 and over, Bundle-Branch Block diagnosis, Electrocardiography, Female, Humans, Male, Retrospective Studies, Treatment Outcome, Transcatheter Aortic Valve Replacement
- Abstract
Background: Current LBBB definitions cannot always distinguish LBBB from left ventricular conduction delay. Only patients with LBBB are expected to normalize with His bundle pacing. Patients who develop new LBBB immediately post transcatheter aortic valve replacement (TAVR) provide an excellent model to define electrocardiogram (ECG) features of LBBB. We sought to describe their ECG features and develop a new ECG definition of LBBB., Methods: We screened ECGs from 264 consecutive patients who underwent TAVR at the University of Ottawa Heart Institute. Patients with a baseline QRS of ≤100 ms who developed QRS ≥120 ms immediately after TAVR were included. Two electrocardiologists reviewed all ECG independently. Baseline demographics and echocardiographic data were retrospectively collected., Results: 36 patients were included in the analysis. The median age was 85.5 years (IQR, 81.8-89 years) and 52.8% were males. The minimum QRS duration was 126 ms. The median QRS axis was -18° (IQR, -40-4.5°), which is 18.5° leftward compared to the median QRS axis before TAVR. Fourteen patients (38.9%) had left axis deviation. All patients had a notched/slurred R wave in at least one lateral lead and an R wave duration of ≤20 ms in V1 when present., Conclusion: We developed a new ECG definition of LBBB that includes 2 novel findings: notching/slurring of the R wave in at least one lateral lead and an R wave ≤20 ms in V1. Further larger studies are warranted to confirm these findings., Competing Interests: Declaration of competing interest None., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
18. High-power short-duration radiofrequency ablation of typical atrial flutter.
- Author
-
Golian M, Ramirez FD, Alqarawi W, Hansom SP, Nery PB, Redpath CJ, Nair GM, Shaw GC, Davis DR, Birnie DH, and Sadek MM
- Abstract
Background: High-power short-duration (HPSD) ablation has been explored for pulmonary vein isolation. Early data suggest similar efficacy with shorter procedure times and perhaps greater safety. Data are lacking on the use of this ablation strategy for other arrhythmias., Objective: The purpose of this study was to evaluate the safety, efficacy, and clinical outcomes of HPSD ablation in patients with typical atrial flutter compared to those undergoing ablation with conventional settings., Methods: Consecutive patients undergoing cavotricuspid isthmus (CTI) ablation using standard power settings were compared to those performed after transitioning to HPSD ablation. Demographics, procedural details, and ablation outcomes were prospectively collected. The primary endpoint was duration of radiofrequency energy delivery. Secondary endpoints were radiation duration and analgesia requirements., Results: A total of 114 consecutive subjects undergoing CTI ablation (57 standard power, 57 HPSD) were included. HPSD ablation and electroanatomic mapping/contact force (EAM/CF) use were associated with 66% (95% confidence interval [CI] 58%-73%) and 50% (95% CI 37%-60%) shorter ablation times compared to standard power and not using EAM/CF, respectively. Patients in the HPSD group required 50 mcg less fentanyl relative to the standard ablation arm after adjusting for sex, age, and comorbidities ( P = .048). At a median follow-up of 6 months, 4 patients (7%) in the standard arm had recurrence of atrial flutter, compared to none in HPSD group ( P = .057)., Conclusion: HPSD is a safe and effective approach to CTI ablation. This strategy may reduce ablation time and analgesia requirements. Larger studies and longer follow-up are needed to further evaluate this strategy., (© 2020 Heart Rhythm Society. Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
19. A Strategy of Lead Abandonment in a Large Cohort of Patients With Sprint Fidelis Leads.
- Author
-
Alqarawi W, Coppens J, Aldawood W, Ramirez FD, Redpath CJ, Nair GM, Nery PB, Davis DR, Abu Shama R, Aydin A, Klein A, Golian M, Schaller RD, Green MS, Birnie DH, and Sadek MM
- Subjects
- Aged, Female, Humans, Male, Medical Device Recalls, Middle Aged, Prospective Studies, Reoperation statistics & numerical data, Defibrillators, Implantable adverse effects, Defibrillators, Implantable standards, Defibrillators, Implantable statistics & numerical data, Device Removal instrumentation, Device Removal methods, Device Removal statistics & numerical data
- Abstract
Objectives: This study sought to examine outcomes of our approach to managing a large cohort of patients with Sprint Fidelis (Medtronic, Minneapolis, Minnesota) leads., Background: The optimal management approach for patients with leads under advisory is unknown. Concerns regarding the risk of device infection and complications associated with delaying lead extraction have recently been suggested to argue against abandoning leads under advisory., Methods: All patients with a Sprint Fidelis lead implanted at our institute were included. Lead management options were discussed with patients who presented for device surgery at the time of device upgrade, lead fracture, or elective replacement indicator. Implantation of a new lead with abandonment of the Sprint Fidelis lead was the recommended strategy. Patients were subsequently followed at the device clinic at 6-month intervals and were enrolled prospectively in a longitudinal registry., Results: A total of 520 patients had Sprint Fidelis leads implanted between December 2003 and October 2007 at the study center; 217 patients underwent lead replacement (213 underwent a lead abandonment strategy and 4 underwent a lead extraction strategy). Mean follow-up after lead replacement was 55 ± 33 months. In patients undergoing lead abandonment, 10 of 213 (4.7%) had a procedural complication and 3 of 213 (1.4%) developed subsequent device infection requiring system extraction., Conclusions: In patients with a Sprint Fidelis lead, implanting a new lead without prophylactic extraction may be a feasible and safe strategy but requires longer follow-up., (Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
20. Evaluation of a novel cardioversion intervention for atrial fibrillation: the Ottawa AF cardioversion protocol.
- Author
-
Ramirez FD, Sadek MM, Boileau I, Cleland M, Nery PB, Nair GM, Redpath CJ, Green MS, Davis DR, Charron K, Henne J, Zakutney T, Beanlands RSB, Hibbert B, Wells GA, and Birnie DH
- Subjects
- Electrocardiography methods, Female, Humans, Male, Middle Aged, Outcome and Process Assessment, Health Care, Quality Improvement, Treatment Outcome, Atrial Fibrillation diagnosis, Atrial Fibrillation therapy, Clinical Protocols standards, Electric Countershock adverse effects, Electric Countershock methods
- Abstract
Aims: Electrical cardioversion is commonly performed to restore sinus rhythm in patients with atrial fibrillation (AF), but it is unsuccessful in 10-12% of attempts. We sought to evaluate the effectiveness and safety of a novel cardioversion protocol for this arrhythmia., Methods and Results: Consecutive elective cardioversion attempts for AF between October 2012 and July 2017 at a tertiary cardiovascular centre before (Phase I) and after (Phase II) implementing the Ottawa AF cardioversion protocol (OAFCP) as an institutional initiative in July 2015 were evaluated. The primary outcome was cardioversion success, defined as ≥2 consecutive sinus beats or atrial-paced beats in patients with implanted cardiac devices. Secondary outcomes were first shock success, sustained success (sinus or atrial-paced rhythm on 12-lead electrocardiogram prior to discharge from hospital), and procedural complications. Cardioversion was successful in 459/500 (91.8%) in Phase I compared with 386/389 (99.2%) in Phase II (P < 0.001). This improvement persisted after adjusting for age, body mass index, amiodarone use, and transthoracic impedance using modified Poisson regression [adjusted relative risk 1.08, 95% confidence interval (CI) 1.05-1.11; P < 0.001] and when analysed as an interrupted time series (change in level +9.5%, 95% CI 6.8-12.1%; P < 0.001). The OAFCP was also associated with greater first shock success (88.4% vs. 79.2%; P < 0.001) and sustained success (91.6% vs 84.7%; P=0.002). No serious complications occurred., Conclusion: Implementing the OAFCP was associated with a 7.4% absolute increase in cardioversion success and increases in first shock and sustained success without serious procedural complications. Its use could safely improve cardioversion success in patients with AF., Clinical Trial Number: www.clinicaltrials.gov ID: NCT02192957., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
21. Atrial Fibrillation Is Associated With Impaired Atrial Mitochondrial Energetics and Supercomplex Formation in Adults With Type 2 Diabetes.
- Author
-
Kanaan GN, Patten DA, Redpath CJ, and Harper ME
- Subjects
- Adult, Atrial Appendage metabolism, Atrial Appendage surgery, Atrial Fibrillation epidemiology, Atrial Fibrillation surgery, Cell Respiration physiology, Diabetes Mellitus, Type 2 epidemiology, Diabetes Mellitus, Type 2 surgery, Female, Humans, Male, Atrial Fibrillation metabolism, Diabetes Mellitus, Type 2 metabolism, Energy Metabolism physiology, Mitochondria, Heart metabolism, Oxidative Stress physiology
- Abstract
Objectives: Type 2 diabetes mellitus is a chronic progressive disease that is associated with increased risk for cardiovascular diseases and with impaired mitochondrial metabolism in cardiac and skeletal muscles. Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated with significant morbidity and mortality. Type 2 diabetes is also one of the prevalent concomitant diseases in patients with AF. During AF, myocardial energy demand is high due to electrical activity. To date, however, very little is known about the effects of AF on atrial muscle mitochondrial energetics. We hypothesized that preexisting fibrillation or type 2 diabetes impacts atrial mitochondrial energetics and electron transport chain supercomplexes., Methods: Atrial appendages were collected from patients who had consented and who had and did not have preexisting AF and were undergoing coronary artery bypass graft surgery. Mitochondrial functional analyses were conducted in permeabilized myofibers using high-resolution respirometry., Results: Results show impaired complex I and II function in addition to impaired electron transport chain supercomplex assembly in patients with diabetes and AF compared to patients with diabetes but without AF. There were no differences in mitochondrial content in atrial muscle between the groups. There was a strong trend for increased oxidative damage (protein carbonyls) in patients with diabetes and AF compared to patients with diabetes but without AF., Conclusions: Overall, findings suggest impaired mitochondrial function in AF and type 2 diabetes., (Copyright © 2018 Diabetes Canada. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
22. Prevalence of left atrial appendage thrombus detected by transoesophageal echocardiography before catheter ablation of atrial fibrillation in patients anticoagulated with non-vitamin K antagonist oral anticoagulants.
- Author
-
Alqarawi W, Birnie DH, Spence S, Ramirez FD, Redpath CJ, Lemery R, Nair GM, Nery PB, Davis DR, Green MS, Beauchesne L, Chan K, Ascah K, Burwash I, and Sadek MM
- Subjects
- Administration, Oral, Aged, Atrial Fibrillation diagnosis, Atrial Fibrillation epidemiology, Catheter Ablation, Databases, Factual, Female, Humans, Male, Middle Aged, Ontario epidemiology, Predictive Value of Tests, Prevalence, Registries, Risk Factors, Anticoagulants administration & dosage, Atrial Appendage diagnostic imaging, Atrial Fibrillation drug therapy, Echocardiography, Transesophageal, Thrombosis diagnostic imaging, Thrombosis epidemiology
- Abstract
Aims: There is ongoing controversy about the need for routine transoesophageal echocardiography (TOE) prior to atrial fibrillation (AF) ablation. Recently, the debate was reignited by the publication of a large series of patients showing a prevalence of left atrial appendage thrombus (LAAT) on TOE of 4.4%. We sought to assess the prevalence of LAAT on TOE before AF ablation at our institution., Methods and Results: Consecutive patients scheduled for AF ablation at our institution between January 2009 and December 2016 were included. All patients were on oral anticoagulation for at least 4 weeks prior to TOE. Transoesophageal echocardiographies were performed 3-5 days prior to scheduled AF ablation. Data were collected utilizing a prospective database. In all, 668 patients and 943 AF ablation procedures were included. Mean age was 64 ± 11 years, 72% were male, average CHADS2 score was 1.0 ± 1.0, and 72% of the patients had paroxysmal AF. At the time of ablation, 496 (53%) were on non-vitamin K antagonist oral anticoagulants (NOACs) and 447 (47%) were on Warfarin. There were three cases with LAAT (3/943, 0.3%), all of whom had persistent AF and were on Warfarin. Two patients underwent surgical ablation and the third patient did not undergo ablation., Conclusion: In our experience, the prevalence of LAAT in patients on anticoagulation therapy undergoing TOE before catheter ablation of AF is 0.3%, which was much lower than recently reported. None of the patients with paroxysmal AF or on NOACs were found to have LAAT. Rather than routine use of TOE prior to AF ablation, a risk-based approach should be considered.
- Published
- 2019
- Full Text
- View/download PDF
23. Completely nonfluoroscopic catheter ablation of left atrial arrhythmias and ventricular tachycardia.
- Author
-
Sadek MM, Ramirez FD, Nery PB, Golian M, Redpath CJ, Nair GM, and Birnie DH
- Subjects
- Aged, Atrial Fibrillation diagnostic imaging, Atrial Fibrillation physiopathology, Atrial Flutter diagnostic imaging, Atrial Flutter physiopathology, Catheter Ablation adverse effects, Feasibility Studies, Female, Humans, Learning Curve, Male, Middle Aged, Operative Time, Tachycardia, Ventricular diagnostic imaging, Tachycardia, Ventricular physiopathology, Time Factors, Treatment Outcome, Ultrasonography, Interventional adverse effects, Workflow, Atrial Fibrillation surgery, Atrial Flutter surgery, Catheter Ablation methods, Echocardiography, Electromagnetic Phenomena, Tachycardia, Ventricular surgery, Ultrasonography, Interventional methods
- Abstract
Introduction: Fluoroscopy use during catheter ablation procedures increases the cumulative lifetime radiation exposure of patients and operators, potentially leading to a higher risk of cancer and radiation-related injuries. Nonfluoroscopic ablation (NFA) has been described for supraventricular tachycardia, typical atrial flutter, paroxysmal atrial fibrillation (AF), and outflow-tract ventricular tachycardia (VT). Complete transition to NFA of more complex arrhythmias, including persistent AF, left atrial (LA) flutter, and structural VT, has not been previously described. We describe the transition to completely NFA of complex arrhythmias, including LA flutter and structural VT. The techniques, challenges, limitations, and results are described., Methods and Results: Complex ablation procedures were performed using intracardiac echocardiography (ICE) and a three-dimensional mapping system without fluoroscopy or lead protection. Eighty consecutive patients underwent NFA (mean age, 60.1 ± 9.9 years, 70 with LA arrhythmias, 10 with VT). All cases were performed without the need for rescue fluoroscopy. There was an initial increase in procedural time for ablation of LA arrhythmias upon transitioning to NFA. However, after excluding the first 20 NFA cases to allow for operator learning, the transition to NFA was not associated with an increase in mean procedural time (229 ± 38 vs 225 ± 32 minutes; P = 0.002 for noninferiority). All procedures were completed successfully with no complications., Conclusions: NFA of most complex arrhythmias (persistent AF, LA flutter, and structural VT) is feasible, with a modest learning curve and no increase in procedural times., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
24. Characterization of Low-Voltage Areas in Patients With Atrial Fibrillation: Insights From High-Density Intracardiac Mapping.
- Author
-
Nery PB, Al Dawood W, Nair GM, Redpath CJ, Sadek MM, Chen L, Green MS, Wells G, and Birnie DH
- Subjects
- Atrial Fibrillation surgery, Female, Humans, Male, Middle Aged, Pulmonary Veins surgery, Reproducibility of Results, Atrial Fibrillation physiopathology, Catheter Ablation methods, Electrophysiologic Techniques, Cardiac methods, Heart Atria physiopathology, Heart Conduction System physiopathology
- Abstract
Background: There is limited data on the scar burden in patients with atrial fibrillation (AF). In this study, we sought to evaluate the presence and extent of an abnormal left atrial (LA) substrate in patients with paroxysmal or persistent AF., Methods: Consecutive patients who underwent initial AF catheter ablation were prospectively enrolled. Endocardial voltage mapping was acquired in sinus rhythm using multipolar mapping catheters. Automated software was used to ensure homogeneous data collection. Assessment of low-voltage area (LVA) was performed by a reviewer blinded to clinical details., Results: One hundred and four patients were prospectively enrolled; 69 had paroxysmal and 35 persistent AF. The mean LA volume was 159 ± 48 mL, and the average number of LA points collected was 1308 ± 1065. Atrial LVAs were present in 23 of 69 (33%) subjects with paroxysmal and 20 of 35 (57%) with persistent AF (P = 0.02). Amongst 43 of 104 patients with scar, the average extent of LVA was 19.4 ± 21.6 cm
2 and the mean percentage area was 7.6 ± 8.8%. Univariate analysis showed that age, LA volume, and persistent AF were associated with the presence of LVA. Multivariable analysis showed that age (odds ratio [OR] 1.05; 95% confidence interval [CI] 1.00-1.11; P = 0.046) and LA volume (OR 1.02; 95% CI 1.01-1.04; P < 0.001) remained predictors of LVA. AF classification (persistent vs paroxysmal) was not a predictor of an abnormal atrial substrate (OR 1.34; 95% CI 0.4-3.9; P = 0.56)., Conclusions: There is wide variability in the presence and extent of LVA in patients with paroxysmal or persistent AF. Age and LA volume were predictors of LVA. There was no correlation between AF classification and the presence of LVA., (Copyright © 2018 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
25. Efficacy and safety of driver-guided catheter ablation for atrial fibrillation: A systematic review and meta-analysis.
- Author
-
Ramirez FD, Birnie DH, Nair GM, Szczotka A, Redpath CJ, Sadek MM, and Nery PB
- Subjects
- Atrial Fibrillation physiopathology, Humans, Randomized Controlled Trials as Topic methods, Treatment Outcome, Atrial Fibrillation surgery, Catheter Ablation instrumentation, Catheter Ablation methods
- Abstract
Introduction: Targeting localized drivers (electrical rotors or focal impulses) during catheter ablation for atrial fibrillation (AF) has been proposed as a strategy to improve procedural success. However, the strength and quality of the evidence to support this approach is unclear., Methods and Results: Clinical studies reporting efficacy or safety outcomes of driver-guided ablation for AF were identified in Medline, Embase, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, Pubmed, and conference abstracts from major scientific meetings. Random-effects meta-analysis of efficacy outcomes from controlled studies was performed. Thirty-one reports from 30 studies were included: two randomized controlled trials, five nonrandomized controlled studies, and 23 uncontrolled studies. In controlled studies, driver-guided ablation has been associated with higher rates of acute AF termination (RR 2.08, 95% CI 1.43-3.05; P < 0.001) and increased freedom from AF/atrial tachycardia (AT) at ≥1 year (RR 1.34, 95% CI 1.05-1.70; P = 0.02). Similar rates of procedural complications have been reported between ablation strategies. Overall, current data on driver-guided ablation are predominantly from nonrandomized studies with considerable heterogeneity in mapping and ablation strategies used and in clinical outcomes reported., Conclusion: Pooled data on the efficacy of AF driver-guided catheter ablation suggest increased freedom from AF/AT relative to conventional strategies. However, most studies are nonrandomized and of moderate quality. Though promising data exist, there remains no conclusive evidence for the efficacy of AF driver ablation. Robust data from randomized trials are needed., (© 2017 Wiley Periodicals, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
26. Crossing the slow pathway bridge: A better method for decreasing long-term recurrences after cryoablation of atrioventricular nodal reentrant tachycardia?
- Author
-
Pang BJ, Redpath CJ, and Green MS
- Subjects
- Atrioventricular Node, Bundle of His, Catheter Ablation, Electrocardiography, Heart Conduction System, Humans, Recurrence, Treatment Outcome, Cryosurgery, Tachycardia, Atrioventricular Nodal Reentry surgery
- Published
- 2017
- Full Text
- View/download PDF
27. Three-year outcomes and reconnection patterns after initial contact force guided pulmonary vein isolation for paroxysmal atrial fibrillation.
- Author
-
Nair GM, Yeo C, MacDonald Z, Ainslie MP, Alqarawi WA, Nery PB, Redpath CJ, Sadek M, Spence S, Green MS, and Birnie DH
- Subjects
- Atrial Fibrillation diagnosis, Atrial Fibrillation physiopathology, Body Surface Potential Mapping methods, Equipment Design, Female, Follow-Up Studies, Heart Conduction System diagnostic imaging, Heart Conduction System physiopathology, Humans, Male, Middle Aged, Pulmonary Veins diagnostic imaging, Retrospective Studies, Tachycardia, Paroxysmal diagnosis, Tachycardia, Paroxysmal physiopathology, Time Factors, Treatment Outcome, Atrial Fibrillation surgery, Catheter Ablation instrumentation, Heart Conduction System surgery, Pulmonary Veins surgery, Tachycardia, Paroxysmal surgery
- Abstract
Background and Objective: Contact force (CF) sensing is a novel technology used for catheter ablation of atrial fibrillation (AF). We compared the single procedure success of CF-guided pulmonary vein isolation (PVI) with that of non-CF guided PVI during a 3-year (1,095 days) follow up period and analyzed the pattern of pulmonary vein (PV) reconnection., Methods: A cohort of 167 subjects (68 CF vs. 99 non-CF) with paroxysmal AF were included in the study. Atrial arrhythmia (AA) recurrence was defined as documented AF, atrial flutter, or atrial tachycardia lasting >30 seconds and occurring after 90 days., Results: Subjects in the CF group showed a statistically nonsignificant improvement in AA free survival compared to those in the non-CF group (66.2% vs. 51.5%; P value: 0.06). A greater propensity for reconnection was noted around the right-sided PVs compared to left-sided PVs related in both catheter ablation groups. For example, in the CF group 36% of right-sided segments reconnected compared to 16% of left-sided segments (P value <0.01)., Conclusions: A greater propensity for reconnection was noted around the right sided PV segments in both the CF and non-CF groups. The explanation for this finding was related to greater catheter instability around the right sided veins. Further research is needed to explore the utility of a "real-time" composite indicator that includes RF energy, CF and catheter stability in predicting transmural lesion formation during catheter ablation., (© 2017 Wiley Periodicals, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
28. Identifying and Managing Premature Ventricular Contraction-Induced Cardiomyopathy: What, Why, and How?
- Author
-
Alqarawi WA, Ramirez FD, Nery PB, Redpath CJ, Sadek MM, Green MS, Birnie DH, and Nair GM
- Subjects
- Cardiomyopathies etiology, Cardiomyopathies physiopathology, Diagnosis, Differential, Echocardiography, Electrocardiography, Ambulatory, Follow-Up Studies, Humans, Male, Middle Aged, Systole, Time Factors, Ventricular Dysfunction, Left diagnosis, Ventricular Dysfunction, Left physiopathology, Ventricular Premature Complexes diagnosis, Ventricular Premature Complexes therapy, Cardiomyopathies diagnosis, Disease Management, Myocardial Contraction, Stroke Volume physiology, Ventricular Dysfunction, Left complications, Ventricular Premature Complexes complications
- Abstract
Premature ventricular contraction (PVC)-induced cardiomyopathy is increasingly being recognized as a reversible cause of left ventricular (LV) systolic dysfunction (LVSD). The diagnosis of PVC-induced cardiomyopathy is considered in subjects with high PVC burdens (> 10,000 per 24 hours) after excluding other known causes of LVSD. PVC suppression is the mainstay of the management of PVC-induced cardiomyopathy, in addition to proven evidence-based medical therapy recommended for subjects with LVSD. Management strategies for PVC-induced cardiomyopathy include medical therapy and/or catheter ablation, with an increasing role for catheter ablation as a first-line therapy in view of the potential for permanent suppression of PVCs. Recovery of LVSD is typically a gradual process over months after effective suppression of PVCs. Last, asymptomatic patients with high PVC burdens and preserved LV systolic function appear to be at low risk over the intermediate term for developing LVSD. However, it is prudent to monitor LV function periodically because of the potential for deterioration of LV function observed during long-term follow-up in some subjects., (Copyright © 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
29. Efficacy of adjunctive measures used to assist pulmonary vein isolation for atrial fibrillation: a systematic review.
- Author
-
Nair GM, Raut R, Bami K, Nery PB, Redpath CJ, Sadek MM, Green MS, and Birnie DH
- Subjects
- Atrial Fibrillation diagnosis, Catheter Ablation methods, Humans, Recurrence, Treatment Outcome, Atrial Fibrillation surgery, Catheter Ablation adverse effects, Postoperative Complications, Pulmonary Veins surgery
- Abstract
Purpose of Review: Pulmonary vein reconnection leading to recurrence of atrial arrhythmias after pulmonary vein isolation (PVI) for atrial fibrillation remains a significant challenge. A number of adjunctive measures during PVI have been used to attempt to reduce pulmonary vein reconnection and recurrence of atrial arrhythmias. We performed a systematic review of the literature and meta-analysis of studies evaluating the efficacy of adjunctive measures used during PVI in reducing recurrent atrial arrhythmias., Recent Findings: Our literature search found four interventions that met the prespecified definition of adjunctive measure: adenosine testing post-PVI, contact force-guided PVI, pacing inexcitability of the ablation line during PVI and additional ablation based on the computed tomography thickness of the pulmonary vein-left atrial appendage ridge. Sixteen studies enrolling 3507 patients met all inclusion and exclusion criteria. PVI performed with adjunctive measures was shown to reduce the 1-year recurrence rate of atrial arrhythmias. The point estimate for the combined relative risk of atrial arrhythmia recurrence was 0.56 [95% confidence interval (CI): 0.43-0.73; P value <0.001] in the PVI with adjunctive measures group., Summary: PVI for atrial fibrillation assisted by adjunctive measures results in clinically significant reduction of recurrent atrial arrhythmias. Additional research is required to assess the relative efficacy of individual or combined adjunctive strategies used during PVI for atrial fibrillation.
- Published
- 2017
- Full Text
- View/download PDF
30. Scar-based catheter ablation for persistent atrial fibrillation.
- Author
-
Nery PB, Thornhill R, Nair GM, Pena E, and Redpath CJ
- Subjects
- Heart Atria, Humans, Treatment Outcome, Atrial Fibrillation surgery, Catheter Ablation, Cicatrix
- Abstract
Purpose of Review: Percutaneous catheter ablation can be an effective treatment for paroxysmal atrial fibrillation. However, catheter ablation for the treatment of persistent atrial fibrillation or long-standing persistent atrial fibrillation is associated with success rates of 45-50% at 1 year. To address the challenge of ablating patients with persistent atrial fibrillation, several approaches have been proposed. Atrial scar-based catheter ablation is a promising strategy for ablation of persistent atrial fibrillation., Recent Findings: In this review, we outline the role of atrial scar/fibrosis in the pathophysiology of atrial fibrillation and how this encouraged clinical studies assessing the atrial substrate using scar-based mapping. We highlight current approaches to voltage mapping of atrial scar in patients with atrial fibrillation. The characteristics, techniques, and outcomes of recently published studies evaluating scar-based catheter ablation strategies for the treatment of atrial fibrillation are discussed. Finally, we explore the role of noninvasive tools such as delayed enhancement MRI to assess the atrial fibrillation substrate., Summary: In summary, the optimal catheter ablation strategy for persistent atrial fibrillation remains unknown. Current data highlight the need for a better understanding of the substrate and mechanisms of arrhythmia maintenance in this population. Atrial scar-based catheter ablation has recently emerged as a promising strategy for ablation of atrial fibrillation. However, the available data have limitations that preclude definitive conclusions regarding the utility of this strategy. Further research is needed to assess the role of scar-based ablation for persistent atrial fibrillation.
- Published
- 2017
- Full Text
- View/download PDF
31. Effect of Applying Force to Self-Adhesive Electrodes on Transthoracic Impedance: Implications for Electrical Cardioversion.
- Author
-
Ramirez FD, Fiset SL, Cleland MJ, Zakutney TJ, Nery PB, Nair GM, Redpath CJ, Sadek MM, and Birnie DH
- Subjects
- Adhesives, Adult, Atrial Fibrillation therapy, Electric Countershock instrumentation, Humans, Male, Middle Aged, Young Adult, Cardiography, Impedance methods, Electric Countershock methods, Electrodes
- Abstract
Background: Current guidelines disagree on the role for applying force to electrodes during electrical cardioversion (ECV) for atrial fibrillation, particularly when using self-adhesive pads. We evaluated the impact of this practice on transthoracic impedance (TTI) with varying force and in individuals with differing body mass indices (BMI). We additionally assessed whether specific prompts could improve physicians' ECV technique., Methods: The study comprised three parts: (1) TTI was measured in 11 participants throughout the respiratory cycle and with variable force applied to self-adhesive electrodes in anteroposterior (AP) and anterolateral (AL) configurations. (2) Three participants in different BMI classes then had TTI measured with prespecified incremental force applied. (3) Ten blinded cardiology trainees simulated ECV on one participant with and without prompting (guideline reminders and force analogies) while force applied and TTI were measured., Results: The AP approach was associated with 13% lower TTI than AL (P < 0.001). Strongly negative correlations were observed between force applied and TTI in the AL position, irrespective of BMI (P ≤ 0.003). In all cases, 80% of the total reduction in TTI observed was achieved with 8 kg-force (∼80 N). All prompts resulted in significantly greater force applied and modest reductions in TTI., Conclusions: Applying force to self-adhesive electrodes reduces TTI and should be considered as a means of improving ECV success. Numerically greater mean force applied with a "push-up" force analogy suggests that "concrete" cues may be useful in improving ECV technique., (© 2016 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
32. Electrophysiological abnormalities in subjects with lone atrial fibrillation - Too little, too late?
- Author
-
Nair GM, Nery PB, Redpath CJ, Sadek MM, and Birnie DH
- Published
- 2016
- Full Text
- View/download PDF
33. Relationship Between Pulmonary Vein Reconnection and Atrial Fibrillation Recurrence: A Systematic Review and Meta-Analysis.
- Author
-
Nery PB, Belliveau D, Nair GM, Bernick J, Redpath CJ, Szczotka A, Sadek MM, Green MS, Wells G, and Birnie DH
- Abstract
Objectives: This study systematically reviewed the prevalence of pulmonary vein (PV) reconnection in subjects with and without AF recurrence and assessed the relationship between PV reconnection and freedom from atrial fibrillation (AF)., Background: Pulmonary vein reconnection is frequently observed in patients experiencing recurrent AF post catheter ablation. However, its prevalence in AF-free patients has not been well studied., Methods: An electronic search was performed for studies describing PV electrical conduction in subjects with and without AF recurrence post PV isolation (PVI)., Results: Eleven of 5,665 articles met selection criteria. A total of 683 subjects were included in the meta-analysis; 379 had AF recurrence, and 304 were AF-free. Among patients with AF recurrence, 324 of 379 patients (85.5%) had at least 1 pulmonary vein reconnected. Among AF-free patients, 178 of 304 patients (58.6%) had at least 1 PV electrically reconnected, and 126 of 304 (41.4%) had durable PVI. The relative risk (RR) of recurrent AF was significantly lower with durable PVI than with PV reconnection (RR: 0.57; 95% confidence interval [CI]: 0.37 to 0.86; p = 0.008). Analysis of 7 studies including exclusively paroxysmal AF patients (n = 470) showed RR of 0.69 (95% CI: 0.45 to 1.05; p = 0.09)., Conclusions: This meta-analysis shows that durable PVI is associated with a lower risk of AF recurrence after catheter ablation. However, the association was modest, and PV electrical reconnection is common, affecting 58% of AF-free patients. Analysis of studies that included exclusively patients with paroxysmal AF showed a weaker relationship. Additional research is warranted to better understand the mechanism(s) of benefit of catheter ablation for AF and investigate whether PVI should be the primary goal., (Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
34. Radiation safety and ergonomics in the electrophysiology laboratory: update on recent advances.
- Author
-
Nair GM, Nery PB, Redpath CJ, Sadek MM, and Birnie DH
- Subjects
- Humans, Risk Factors, Safety, Electrophysiologic Techniques, Cardiac methods, Electrophysiology standards, Ergonomics methods, Radiation Dosage, Radiation Protection methods
- Abstract
Purpose of Review: Risks associated with exposure to ionizing radiation in patients undergoing electrophysiology procedures and interventional cardiac electrophysiologists performing these procedures are a serious concern. Strategies to reduce radiation exposure are of obvious importance. In addition, interventional cardiac electrophysiologists have to perform procedures wearing heavy lead protection for prolonged periods, making them prone to cervical and lumbar spinal injuries., Recent Findings: Recently developed technologies, such as low-exposure radiographic imaging, novel radiographic imaging protection systems, nonfluoroscopic mapping systems using image integration, and remote catheter manipulation systems have been successful in reducing ionizing radiation exposure in the electrophysiology laboratory. The efficacy and safety of these technologies are being evaluated in clinical trials. In addition, economic analyses are being performed to evaluate these novel systems. The use of nonweight-bearing radiation protection devices and ergonomic design of the electrophysiology laboratory aim to reduce the incidence of occupational injuries in interventional cardiac electrophysiologists., Summary: There is need for ongoing development and evaluation of new technologies to minimize exposure to ionizing radiation during electrophysiologic procedures. In addition, ergonomic planning of the electrophysiology laboratory and training of interventional cardiac electrophysiologists are crucial to occupational injury prevention.
- Published
- 2016
- Full Text
- View/download PDF
35. The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, Canada.
- Author
-
Huang AR, Redpath CJ, and van Walraven C
- Subjects
- Aged, Comorbidity, Databases, Factual, Dementia complications, Donepezil, Female, Galantamine therapeutic use, Health Services Research, Humans, Indans therapeutic use, Male, Ontario, Piperidines therapeutic use, Retrospective Studies, Risk, Rivastigmine therapeutic use, Cholinesterase Inhibitors therapeutic use, Dementia drug therapy, Pacemaker, Artificial, Prosthesis Implantation adverse effects
- Abstract
Background: Cholinesterase inhibitors are used to treat the symptoms of dementia and can theoretically cause bradycardia. Previous studies suggest that patients taking these medications have an increased risk of undergoing pacemaker insertion. Since these drugs have a marginal impact on patient outcomes, it might be preferable to change drug treatment rather than implant a pacemaker. This population-based study determined the association of people with dementia exposed to cholinesterase inhibitor medication and pacemaker insertion., Methods: We used data from the Ontario health administrative databases from January 1, 1993 to June 30, 2012. We included all community-dwelling seniors who had a code for dementia and were exposed to cholinesterase inhibitors (donezepil, galantamine, and rivastigmine) and/or drugs used to treat co-morbidities of hypertension, diabetes, depression and hypothyroidism. We controlled for exposure to anti-arrhythmic drugs. Observation started at first exposure to any medication and continued until the earliest of pacemaker insertion, death, or end of study., Results: 2,353,909 people were included with 96,000 (4.1%) undergoing pacemaker insertion during the observation period. Case-control analysis showed that pacemaker patients were less likely to be coded with dementia (unadjusted OR 0.42 [95%CI 0.41-0.42]) or exposed to cholinesterase inhibitors (unadjusted OR 0.39 [95%CI 0.37-0.41]). That Cohort analysis showed patients with dementia taking cholinesterase inhibitors had a decreased risk of pacemaker insertion (unadj-HR 0.58 [0.55-0.61]). Adjustment for patient age, sex, and other medications did not notably change results, as did restricting the analysis to incident users., Conclusions: Patients taking cholinesterase inhibitors rarely undergo, and have a significantly reduced risk of, cardiac pacemaker insertion.
- Published
- 2015
- Full Text
- View/download PDF
36. Atrial fibrillation and the athletic heart.
- Author
-
Redpath CJ and Backx PH
- Subjects
- Adult, Athletes statistics & numerical data, Disease Progression, Exercise Tolerance physiology, Female, Humans, Incidence, Male, Patient Safety, Physical Education and Training standards, Physical Education and Training trends, Risk Assessment, Severity of Illness Index, Survival Rate, Young Adult, Atrial Fibrillation epidemiology, Atrial Fibrillation physiopathology, Physical Endurance physiology, Sports physiology
- Abstract
Purpose of Review: Endurance exercise, despite a plethora of proven health benefits, is increasingly recognized as a potential cause of lone atrial fibrillation. Moderate exercise reduces all-cause mortality and protects against developing atrial fibrillation. However, more intense exercise regimes confer modest incremental health benefits, induce cardiac remodelling and negate some of the cardiovascular benefits of exercise. The implications of endurance exercise and athletic heart are becoming increasingly relevant as the popularity of endurance exercise has increased 20-fold within a generation., Recent Findings: An apparent dose-response relationship exists between endurance exercise and left atrial dilatation. Repeated strenuous endurance exercise overloads atria, resulting in stretch-induced 'microtears', inflammation and endocardial scarring. Although these findings are observational in humans, similar mechanisms have recently been confirmed in animal models suggesting causation., Summary: Currently, it is not known whether a ceiling for endurance exercise exists, and, if so, what factors determine the threshold of harm. Although preliminary research is promising, much work remains if we are to understand the mechanisms underpinning atrial fibrillation in athletes.
- Published
- 2015
- Full Text
- View/download PDF
37. Cardiac resynchronization therapy in a patient with persistent left superior vena cava draining into the coronary sinus and absent innominate vein: a case report and review of literature.
- Author
-
Nair GM, Shen S, Nery PB, Redpath CJ, and Birnie DH
- Abstract
Introduction: Persistent left superior vena cava (PLSVC) is a rare congenital anomaly of the superior venous system that may be discovered at the time of cardiac implantable electronic device (CIED) implantation., Methods and Results: We present a subject who needed cardiac resynchronization therapy (CRT)-CIED implantation and was discovered to have PLSVC with absent innominate vein during the implant procedure. We were able to successfully implant a CRT-CIED using a right-sided approach via the right superior vena cava (SVC). We present a description of our implant technique and a brief review of the different aspects of CIED implantation in subjects with variants of PLSVC., Conclusion: Superior venous anomalies such as PLSVC can make CIED implantation technically challenging. However, with increasing operator experience, cardiac imaging and appropriate tools successful CIED implantation is possible in almost all cases.
- Published
- 2014
- Full Text
- View/download PDF
38. Stenting for atrioesophageal fistula--reply to letter from Elitzur et al.
- Author
-
Nair GM, Nery PB, Redpath CJ, Lam BK, and Birnie DH
- Subjects
- Humans, Atrial Fibrillation surgery, Catheter Ablation adverse effects, Esophageal Fistula etiology, Fistula etiology, Heart Atria, Heart Diseases etiology
- Published
- 2014
- Full Text
- View/download PDF
39. The Role Of Renin Angiotensin System In Atrial Fibrillation.
- Author
-
Nair GM, Nery PB, Redpath CJ, and Birnie DH
- Abstract
Atrial fibrillation (AF) is the most prevalent arrhythmia and its incidence is on the rise. AF causes significant morbidity and mortality leading to rising AF-related health care costs. There is experimental and clinical evidence from animal and human studies that suggests a role for the renin angiotensin system (RAS) in the etiopathogenesis of AF. This review appraises the current understanding of RAS antagonism, using angiotensin converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB) and aldosterone antagonists (AA), for prevention of AF. RAS antagonism has proven to be effective for primary and secondary prevention of AF in subjects with heart failure and left ventricular (LV) dysfunction.However, most of the evidence for the protective effect of RAS antagonism is from clinical trials that had AF as a secondary outcome or from unspecified post-hoc analyses. The evidence for prevention in subjects without heart failure and with normal LV function is not as clear. RAS antagonism, in the absence of concomitant antiarrhythmic therapy, was not shown to reduce post cardioversion AF recurrences. RAS antagonism in subjects undergoing catheter ablation has also been ineffective in preventing AF recurrences.
- Published
- 2014
- Full Text
- View/download PDF
40. Atrioesophageal fistula in the era of atrial fibrillation ablation: a review.
- Author
-
Nair GM, Nery PB, Redpath CJ, Lam BK, and Birnie DH
- Subjects
- Body Temperature, Catheter Ablation methods, Deglutition Disorders etiology, Diagnostic Imaging, Esophageal Fistula diagnosis, Esophageal Fistula physiopathology, Esophageal Fistula therapy, Fistula diagnosis, Fistula physiopathology, Fistula therapy, Heart Diseases diagnosis, Heart Diseases physiopathology, Heart Diseases therapy, Humans, Intraoperative Complications prevention & control, Leukocytosis etiology, Monitoring, Intraoperative, Mucous Membrane injuries, Preoperative Care, Atrial Fibrillation surgery, Catheter Ablation adverse effects, Esophageal Fistula etiology, Fistula etiology, Heart Atria, Heart Diseases etiology
- Abstract
The purpose of this review is to understand the epidemiology, clinical features, etiopathogenesis, and management of atrioesophageal fistula (AEF) after atrial fibrillation (AF) ablation. The incidence of AEF after AF ablation is 0.015%-0.04%. The principal clinical features include fever, dysphagia, upper gastrointestinal bleeding, sepsis, and embolic strokes. The close proximity of the esophagus to the posterior left atrial wall is responsible for esophageal injury during ablation. Prophylactic proton pump inhibitors, esophageal temperature monitoring, visualization of the esophagus during catheter ablation, esophageal protection devices, and avoidance of energy delivery in close proximity to the esophagus play an important role in preventing esophageal injury. Early surgical repair or esophageal stenting are the mainstay of treatment. Eliminating esophageal injury during AF ablation is of utmost importance in preventing AEF. A high index of suspicion and early intervention is necessary to prevent fatal outcomes., (Copyright © 2014 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
41. Ventricular arrhythmias in patients with heart failure secondary to reduced ejection fraction: a current perspective.
- Author
-
Nair GM, Nery PB, Redpath CJ, and Birnie DH
- Subjects
- Cardiac Resynchronization Therapy, Cardiomyopathies etiology, Defibrillators, Implantable adverse effects, Humans, Stroke Volume, Heart Failure complications, Ventricular Premature Complexes etiology, Ventricular Premature Complexes therapy
- Abstract
Purpose of Review: To review the management of ventricular arrhythmias in patients with heart failure secondary to reduced ejection fraction (HFrEF)., Recent Findings: Recurrent ventricular arrhythmias and automatic implantable cardioverter defibrillator (AICD) shocks are responsible for significant mortality and morbidity in patients with HFrEF. Antiarrhythmic drugs and catheter ablation are the main treatment options. Frequent premature ventricular contractions (PVCs; >10,000-20,000/24-h period) are being recognized as a cause of cardiomyopathy and suboptimal response to cardiac resynchronization therapy (CRT). Patients with ventricular assist devices (VADs) have frequent ventricular tachyarrhythmias resulting in increased morbidity and mortality. Such patients may need continuation of active ICD therapy and adjunctive catheter ablation., Summary: There is a pressing need to develop new antiarrhythmic drugs to treat patients with recurrent AICD shocks. The effectiveness of catheter ablation as first-line therapy for preventing ventricular arrhythmias and recurrent AICD shocks needs to be directly compared with amiodarone. Ventricular tachyarrhythmias are common in CRT patients and patients with VADs. Frequent PVCs may result in a reversible form of HFrEF.
- Published
- 2014
- Full Text
- View/download PDF
42. Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia.
- Author
-
Nery PB, Mc Ardle BA, Redpath CJ, Leung E, Lemery R, Dekemp R, Yang J, Keren A, Beanlands RS, and Birnie DH
- Subjects
- Cardiomyopathies, Causality, Comorbidity, Female, Humans, Male, Middle Aged, Ontario epidemiology, Prevalence, Risk Assessment, Sarcoidosis diagnosis, Sarcoidosis epidemiology, Tachycardia, Ventricular diagnosis, Tachycardia, Ventricular epidemiology
- Abstract
Introduction: Sarcoidosis is a granulomatous disease of unknown etiology, which involves the heart in 5-25% of cases. Although ventricular tachycardia (VT) has been reported as the first presentation of sarcoidosis, its prevalence has not previously been investigated. In this prospective study, we sought to systematically investigate the prevalence of cardiac sarcoidosis (CS) in patients presenting with monomorphic VT (MMVT) and no previous history of sarcoidosis., Methods: Consecutive patients presenting with MMVT to a tertiary care center were screened for inclusion. Patients with idiopathic VT, VT secondary to coronary artery disease, or prior diagnosis of sarcoidosis were excluded. Included patients underwent F-18-fluorodeoxyglucose positron emission tomography (PET) scan. In subjects with PET scanning suggestive of active myocardial inflammation, histological diagnosis was confirmed through extracardiac or endomyocardial biopsy (EMB)., Results: A total of 182 patients presented to our institution with VT between February 2010 and September 2012 and 14 subjects met inclusion criteria. Within this group, six of 14 (42%) patients had abnormal PET scans suggesting active myocardial inflammation. Four of the six patients had tissue biopsies that were diagnostic of sarcoidosis; the remaining two patients had guided EMB indicating nonspecific myocarditis. Atrioventricular block was observed in three of four (75%) patients with CS and none in 10 of the others (P = 0.022). Three of the four patients had pulmonary sarcoidosis and one patient had isolated CS. All four patients were treated with corticosteroids., Conclusion: In this prospective study, four of 14 (28%) patients presenting with MMVT (without idiopathic VT, ischemic VT, or known sarcoidosis) had CS as the underlying etiology. Clinicians should consider screening for CS in patients with unexplained MMVT., (©2013, The Authors. Journal compilation ©2013 Wiley Periodicals, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
43. Mitochondrial hyperfusion during oxidative stress is coupled to a dysregulation in calcium handling within a C2C12 cell model.
- Author
-
Redpath CJ, Bou Khalil M, Drozdzal G, Radisic M, and McBride HM
- Subjects
- Acetylcysteine pharmacology, Animals, Calcium Signaling drug effects, Cell Differentiation drug effects, Mice, Mitochondria drug effects, Mitochondria ultrastructure, Mitochondrial Dynamics drug effects, Mitochondrial Membranes drug effects, Mitochondrial Membranes metabolism, Muscle Contraction drug effects, Muscle Fibers, Skeletal cytology, Muscle Fibers, Skeletal ultrastructure, Mutant Proteins metabolism, Oxidation-Reduction drug effects, Protein Transport drug effects, Reactive Oxygen Species metabolism, Sarcoplasmic Reticulum drug effects, Sarcoplasmic Reticulum metabolism, Calcium metabolism, Mitochondria metabolism, Models, Biological, Muscle Fibers, Skeletal metabolism, Oxidative Stress drug effects
- Abstract
Atrial Fibrillation is the most common sustained cardiac arrhythmia worldwide harming millions of people every year. Atrial Fibrillation (AF) abruptly induces rapid conduction between atrial myocytes which is associated with oxidative stress and abnormal calcium handling. Unfortunately this new equilibrium promotes perpetuation of the arrhythmia. Recently, in addition to being the major source of oxidative stress within cells, mitochondria have been observed to fuse, forming mitochondrial networks and attach to intracellular calcium stores in response to cellular stress. We sought to identify a potential role for rapid stimulation, oxidative stress and mitochondrial hyperfusion in acute changes to myocyte calcium handling. In addition we hoped to link altered calcium handling to increased sarcoplasmic reticulum (SR)-mitochondrial contacts, the so-called mitochondrial associated membrane (MAM). We selected the C2C12 murine myotube model as it has previously been successfully used to investigate mitochondrial dynamics and has a myofibrillar system similar to atrial myocytes. We observed that rapid stimulation of C2C12 cells resulted in mitochondrial hyperfusion and increased mitochondrial colocalisation with calcium stores. Inhibition of mitochondrial fission by transfection of mutant DRP1K38E resulted in similar effects on mitochondrial fusion, SR colocalisation and altered calcium handling. Interestingly the effects of 'forced fusion' were reversed by co-incubation with the reducing agent N-Acetyl cysteine (NAC). Subsequently we demonstrated that oxidative stress resulted in similar reversible increases in mitochondrial fusion, SR-colocalisation and altered calcium handling. Finally, we believe we have identified that myocyte calcium handling is reliant on baseline levels of reactive oxygen species as co-incubation with NAC both reversed and retarded myocyte response to caffeine induced calcium release and re-uptake. Based on these results we conclude that the coordinate regulation of mitochondrial fusion and MAM contacts may form a point source for stress-induced arrhythmogenesis. We believe that the MAM merits further investigation as a therapeutic target in AF-induced remodelling.
- Published
- 2013
- Full Text
- View/download PDF
44. The use of a novel nitinol guidewire to facilitate transseptal puncture and left atrial catheterization for catheter ablation procedures.
- Author
-
Wadehra V, Buxton AE, Antoniadis AP, McCready JW, Redpath CJ, Segal OR, Rowland E, Lowe MD, Lambiase PD, and Chow AW
- Subjects
- Adult, Aged, Aged, 80 and over, Cardiac Catheterization adverse effects, Cardiac Catheterization instrumentation, Equipment Failure, Female, Fluoroscopy, Humans, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Alloys, Atrial Fibrillation surgery, Atrial Septum, Cardiac Catheterization methods, Catheter Ablation methods, Heart Atria, Punctures instrumentation
- Abstract
Aims: An increasing number of transseptal punctures (TSPs) are performed worldwide for atrial ablations. Transseptal punctures can be complex and can be associated with potentially life threatening complications. The purpose of the study was to evaluate the safety and efficacy of a novel transseptal guidewire (TSGW) designed to facilitate TSPs., Methods and Results: Transseptal punctures were performed using a SafeSept TSGW passed through a standard TSP apparatus. Transseptal punctures were performed by standard technique with additional use of a TSGW allowing probing of the interatrial septum without needle exposure and penetration of the fossa into the left atrium (LA). Transseptal puncture using the TSGW was performed in 210 patients. Left atrial access was achieved successfully in 205 of 210 patients (97.6%) and in 96.3% of patients undergoing repeat TSP. Left atrial access was achieved with the first pass in 81.2% (mean 1.4 ± 0.9 passes, range 1-6) using the TSGW. No serious complications were attributable to the use of the TSGW, even in cases of failed TSP., Conclusions: The TSGW is associated with a high success rate for TSP and may be a useful alternative to transoesophageal or intracardiac echocardiogram-guided TSP.
- Published
- 2011
- Full Text
- View/download PDF
45. The short QT syndrome: proposed diagnostic criteria.
- Author
-
Gollob MH, Redpath CJ, and Roberts JD
- Subjects
- Adolescent, Adult, Arrhythmias, Cardiac genetics, Arrhythmias, Cardiac physiopathology, Electrocardiography, Female, Humans, Male, Arrhythmias, Cardiac diagnosis
- Abstract
Objectives: We aimed to develop diagnostic criteria for the short QT syndrome (SQTS) to facilitate clinical evaluation of suspected cases., Background: The SQTS is a cardiac channelopathy associated with atrial fibrillation and sudden cardiac death. Ten years after its original description, a consensus regarding an appropriate QT interval cutoff and specific diagnostic criteria have yet to be established., Methods: The MEDLINE database was searched for all reported cases of SQTS in the English language, and all relevant data were extracted. The distribution of QT intervals and electrocardiographic (ECG) features in affected cases were analyzed and compared to data derived from ECG analysis from general population studies., Results: A total of 61 reported cases of SQTS were identified. Index events, including sudden cardiac death, aborted cardiac arrest, syncope, and/or atrial fibrillation occurred in 35 of 61 (57.4%) cases. The cohort was predominantly male (75.4%) and had a mean QT(c) value of 306.7 ms with values ranging from 248 to 381 ms in symptomatic cases. In reference to the ECG characteristics of the general population, and in consideration of clinical presentation, family history, and genetic findings, a highly sensitive diagnostic scoring system was developed., Conclusions: Based on a comprehensive review of 61 reported cases of the SQTS, formal diagnostic criteria have been proposed that will facilitate diagnostic evaluation in suspected cases of SQTS. Diagnostic criteria may lead to a greater recognition of this condition and provoke screening of at-risk family members., (Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
46. Rapid genetic testing facilitating the diagnosis of short QT syndrome.
- Author
-
Redpath CJ, Green MS, Birnie DH, and Gollob MH
- Subjects
- Adult, Arrhythmias, Cardiac genetics, Arrhythmias, Cardiac physiopathology, Arrhythmias, Cardiac therapy, Defibrillators, Implantable, ERG1 Potassium Channel, Ether-A-Go-Go Potassium Channels genetics, Exercise Test, Heart Rate, Humans, Male, Sequence Analysis, DNA, Syncope genetics, Arrhythmias, Cardiac diagnosis
- Abstract
Short QT syndrome (SQTS) is a rare genetic disease with a risk of sudden cardiac death. The present report describes syncope in a young man that resulted in a motor vehicle accident. An electrocardiogram and initial investigations were unremarkable, but treadmill testing showed a lack of adaptation of the QT interval, which has been described in SQTS. To evaluate the possible diagnosis of SQTS, DNA sequencing of genes known to be associated with SQTS was performed and identified a novel mutation in the KCNH2 gene. Consequently, the patient was diagnosed with SQTS and the recommendation of implantable cardioverter defibrillator implantation was accepted by the patient before discharge from the hospital.
- Published
- 2009
- Full Text
- View/download PDF
47. Atrial cellular electrophysiological changes in patients with ventricular dysfunction may predispose to AF.
- Author
-
Workman AJ, Pau D, Redpath CJ, Marshall GE, Russell JA, Norrie J, Kane KA, and Rankin AC
- Subjects
- Action Potentials, Angiotensin II Type 1 Receptor Blockers therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Calcium Channel Blockers therapeutic use, Chi-Square Distribution, Female, Heart Atria cytology, Heart Atria physiopathology, Humans, Linear Models, Male, Middle Aged, Patch-Clamp Techniques, Potassium Channels metabolism, Risk Factors, Ventricular Dysfunction, Left drug therapy, Ventricular Dysfunction, Left surgery, Atrial Fibrillation etiology, Atrial Fibrillation physiopathology, Myocytes, Cardiac physiology, Ventricular Dysfunction, Left complications, Ventricular Dysfunction, Left physiopathology
- Abstract
Background: Left ventricular systolic dysfunction (LVSD) is a risk factor for atrial fibrillation (AF), but the atrial cellular electrophysiological mechanisms in humans are unclear., Objective: This study sought to investigate whether LVSD in patients who are in sinus rhythm (SR) is associated with atrial cellular electrophysiological changes that could predispose to AF., Methods: Right atrial myocytes were obtained from 214 consenting patients in SR who were undergoing cardiac surgery. Action potentials or ion currents were measured using the whole-cell-patch clamp technique., Results: The presence of moderate or severe LVSD was associated with a shortened atrial cellular effective refractory period (ERP) (209 +/- 8 ms; 52 cells, 18 patients vs 233 +/- 7 ms; 134 cells, 49 patients; P <0.05); confirmed by multiple linear regression analysis. The left ventricular ejection fraction (LVEF) was markedly lower in patients with moderate or severe LVSD (36% +/- 4%, n = 15) than in those without LVSD (62% +/- 2%, n = 31; P <0.05). In cells from patients with LVEF
45%, by 24% and 18%, respectively. The LVEF and ERP were positively correlated (r = 0.65, P <0.05). The L-type calcium ion current, inward rectifier potassium ion current, and sustained outward ion current were unaffected by LVSD. The transient outward potassium ion current was decreased by 34%, with a positive shift in its activation voltage, and no change in its decay kinetics., Conclusion: LVSD in patients in SR is independently associated with a shortening of the atrial cellular ERP, which may be expected to contribute to a predisposition to AF. - Published
- 2009
- Full Text
- View/download PDF
48. Post-operative atrial fibrillation is influenced by beta-blocker therapy but not by pre-operative atrial cellular electrophysiology.
- Author
-
Workman AJ, Pau D, Redpath CJ, Marshall GE, Russell JA, Kane KA, Norrie J, and Rankin AC
- Subjects
- Action Potentials physiology, Age Factors, Aged, Atrial Fibrillation diagnosis, Female, Heart Atria cytology, Humans, Male, Middle Aged, Myocytes, Cardiac physiology, Postoperative Complications diagnosis, Adrenergic beta-Antagonists adverse effects, Atrial Fibrillation chemically induced, Atrial Fibrillation physiopathology, Postoperative Complications chemically induced, Postoperative Complications physiopathology, Preoperative Care methods
- Abstract
Introduction: We investigated whether post-cardiac surgery (CS) new-onset atrial fibrillation (AF) is predicted by pre-CS atrial cellular electrophysiology, and whether the antiarrhythmic effect of beta-blocker therapy may involve pre-CS pharmacological remodeling., Methods and Results: Atrial myocytes were obtained from consenting patients in sinus rhythm, just prior to CS. Action potentials and ion currents were recorded using whole-cell patch-clamp technique. Post-CS AF occurred in 53 of 212 patients (25%). Those with post-CS AF were older than those without (67 +/- 2 vs 62 +/- 1 years, P = 0.005). In cells from patients with post-CS AF, the action potential duration at 50% and 90% repolarization, maximum upstroke velocity, and effective refractory period (ERP) were 13 +/- 4 ms, 217 +/- 16 ms, 185 +/- 10 V/s, and 216 +/- 14 ms, respectively (n = 30 cells, 11 patients). Peak L-type Ca(2+) current, transient outward and inward rectifier K(+) currents, and the sustained outward current were -5.0 +/- 0.5, 12.9 +/- 2.4, -4.1 +/- 0.4, and 9.7 +/- 1.0 pA/pF, respectively (13-62 cells, 7-19 patients). None of these values were significantly different in cells from patients without post-CS AF (P > 0.05 for each, 60-279 cells, 29-86 patients), confirmed by multiple and logistic regression. In patients treated >7 days with a beta-blocker pre-CS, the incidence of post-CS AF was lower than in non-beta-blocked patients (13% vs 27%, P = 0.038). Pre-CS beta-blockade was associated with a prolonged pre-CS atrial cellular ERP (P = 0.001), by a similar degree (approximately 20%) in those with and without post-CS AF., Conclusion: Pre-CS human atrial cellular electrophysiology does not predict post-CS AF. Chronic beta-blocker therapy is associated with a reduced incidence of post-CS AF, unrelated to a pre-CS ERP-prolonging effect of this treatment.
- Published
- 2006
- Full Text
- View/download PDF
49. Anti-adrenergic effects of endothelin on human atrial action potentials are potentially anti-arrhythmic.
- Author
-
Redpath CJ, Rankin AC, Kane KA, and Workman AJ
- Subjects
- Action Potentials drug effects, Aged, Anti-Arrhythmia Agents pharmacology, Atrial Fibrillation drug therapy, Calcium Channels metabolism, Endothelin-1 metabolism, Female, Humans, Isoproterenol pharmacology, Male, Middle Aged, Adrenergic beta-Antagonists pharmacology, Arrhythmias, Cardiac drug therapy, Endothelins metabolism, Heart Atria drug effects, Heart Atria pathology
- Abstract
Endothelin-1 (ET-1) is elevated in patients with atrial fibrillation (AF) and heart failure. We investigated effects of ET-1 on human atrial cellular electrophysiological measurements expected to influence the genesis and maintenance of AF. Action potential characteristics and L-type Ca(2+) current (I(CaL)) were recorded by whole cell patch clamp, in atrial isolated myocytes obtained from patients in sinus rhythm. Isoproterenol (ISO) at 0.05 muM prolonged the action potential duration at 50% repolarisation (APD(50): 54 +/- 10 vs. 28 +/- 5 ms; P < 0.05, N = 15 cells, 10 patients), but neither late repolarisation nor cellular effective refractory period (ERP) were affected. ET-1 (10 nM) reversed the effect of ISO on APD(50), and had no basal effect (in the absence of ISO) on repolarisation or ERP. During repetitive stimulation, ISO (0.05 microM) produced arrhythmic depolarisations (P < 0.05). Each was abolished by ET-1 at 10 nM (P < 0.05). ISO (0.05 microM) increased peak I(CaL) from -5.5 +/- 0.4 to -14.6 +/- 0.9 pA/pF (P < 0.05; N = 79 cells, 34 patients). ET-1 (10 nM) reversed this effect by 98 +/- 10% (P < 0.05), with no effect on basal I(CaL). Chronic treatment of patients with a beta-blocker did not significantly alter basal APD(50) or I(CaL), the increase in APD(50) or I(CaL) by 0.05 microM ISO, nor the subsequent reversal of this effect on APD(50) by 10 nM ET-1. The marked anti-adrenergic effects of ET-1 on human atrial cellular action potential plateau, arrhythmic depolarisations and I(CaL), without affecting ERP and independently of beta-blocker treatment, may be expected to contribute a potentially anti-arrhythmic influence in the atria of patients with AF and heart failure.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.